Long-term outcome of patients with relapsed and refractory germ cell tumors treated with high-dose chemotherapy and autologous bone marrow rescue

E. Randolph Broun, Craig R. Nichols, Patricia Kneebone, Stephen D. Williams, Patrick Loehrer, Lawrence Einhorn, Guido J K Tricot

Research output: Contribution to journalArticle

155 Citations (Scopus)

Abstract

Objective: To review the long-term outcome of patients with recurrent and refractory germ cell tumors treated with high-dose chemotherapy and autologous bone marrow rescue. ■ Design: Cohort study. ■ Setting: A university hospital. ■ Patients: Forty consecutive patients with recurrent or refractory germ cell tumors treated at Indiana University between September 1986 and June 1989. ■ Interventions: Patients were treated with high-dose carboplatin (900 to 2000 mg/m2 body surface area) and etoposide (1200 mg/m2). Three patients also received ifosfamide (10g/m2). All patients had autologous bone marrow rescue. Of the 40 study patients, 26 received two full courses of therapy. ■ Measurements: Patient charts were reviewed to determine the rate and duration of complete and partial remission and the number of long-term, disease-free survivors. The influence of cisplatin-refractory disease and the site of the primary tumor on the incidence of remission and survival were also investigated. ■ Results: Of the 40 study patients, 26 (65%) responded to treatment; 12 (30%) achieved a complete response, and 14 (35%) achieved a partial response. Of the 12 complete responders, 5 relapsed, and 1 died of treatment-related acute leukemia 27.5 months after treatment without evidence of germ cell cancer. Six (15%) of the original 40 patients, of whom 3 were refractory to cisplatin, remained in complete remission after at least 24 months of follow-up. Eight of 40 patients had primary mediastinal germ cell tumors with no complete remissions and a median survival of 2 months (range, 0.5 to 9.0 months). ■ Conclusions: Treatment with high-dose carboplatin and etoposide in conjunction with autologous bone marrow rescue in patients with relapsed or refractory germ cell tumors is a potentially curative therapeutic option, even for heavily pretreated or cisplatin-refractory patients. Some degree of disease resistance to cisplatin can be overcome with dose escalation of platinum compounds. Patients with multiple recurrences of relapsed or refractory primary mediastinal germ cell tumors were not helped by this approach.

Original languageEnglish
Pages (from-to)124-128
Number of pages5
JournalAnnals of Internal Medicine
Volume117
Issue number2
StatePublished - Jul 15 1992

Fingerprint

Germ Cell and Embryonal Neoplasms
Bone Marrow
Drug Therapy
Cisplatin
Carboplatin
Etoposide
Therapeutics
Platinum Compounds
Ifosfamide
Disease Resistance
Survival
Body Surface Area
Survivors
Leukemia
Cohort Studies

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Long-term outcome of patients with relapsed and refractory germ cell tumors treated with high-dose chemotherapy and autologous bone marrow rescue. / Broun, E. Randolph; Nichols, Craig R.; Kneebone, Patricia; Williams, Stephen D.; Loehrer, Patrick; Einhorn, Lawrence; Tricot, Guido J K.

In: Annals of Internal Medicine, Vol. 117, No. 2, 15.07.1992, p. 124-128.

Research output: Contribution to journalArticle

Broun, E. Randolph ; Nichols, Craig R. ; Kneebone, Patricia ; Williams, Stephen D. ; Loehrer, Patrick ; Einhorn, Lawrence ; Tricot, Guido J K. / Long-term outcome of patients with relapsed and refractory germ cell tumors treated with high-dose chemotherapy and autologous bone marrow rescue. In: Annals of Internal Medicine. 1992 ; Vol. 117, No. 2. pp. 124-128.
@article{d9aecb2be1a946d2b6e253766843772c,
title = "Long-term outcome of patients with relapsed and refractory germ cell tumors treated with high-dose chemotherapy and autologous bone marrow rescue",
abstract = "Objective: To review the long-term outcome of patients with recurrent and refractory germ cell tumors treated with high-dose chemotherapy and autologous bone marrow rescue. ■ Design: Cohort study. ■ Setting: A university hospital. ■ Patients: Forty consecutive patients with recurrent or refractory germ cell tumors treated at Indiana University between September 1986 and June 1989. ■ Interventions: Patients were treated with high-dose carboplatin (900 to 2000 mg/m2 body surface area) and etoposide (1200 mg/m2). Three patients also received ifosfamide (10g/m2). All patients had autologous bone marrow rescue. Of the 40 study patients, 26 received two full courses of therapy. ■ Measurements: Patient charts were reviewed to determine the rate and duration of complete and partial remission and the number of long-term, disease-free survivors. The influence of cisplatin-refractory disease and the site of the primary tumor on the incidence of remission and survival were also investigated. ■ Results: Of the 40 study patients, 26 (65{\%}) responded to treatment; 12 (30{\%}) achieved a complete response, and 14 (35{\%}) achieved a partial response. Of the 12 complete responders, 5 relapsed, and 1 died of treatment-related acute leukemia 27.5 months after treatment without evidence of germ cell cancer. Six (15{\%}) of the original 40 patients, of whom 3 were refractory to cisplatin, remained in complete remission after at least 24 months of follow-up. Eight of 40 patients had primary mediastinal germ cell tumors with no complete remissions and a median survival of 2 months (range, 0.5 to 9.0 months). ■ Conclusions: Treatment with high-dose carboplatin and etoposide in conjunction with autologous bone marrow rescue in patients with relapsed or refractory germ cell tumors is a potentially curative therapeutic option, even for heavily pretreated or cisplatin-refractory patients. Some degree of disease resistance to cisplatin can be overcome with dose escalation of platinum compounds. Patients with multiple recurrences of relapsed or refractory primary mediastinal germ cell tumors were not helped by this approach.",
author = "Broun, {E. Randolph} and Nichols, {Craig R.} and Patricia Kneebone and Williams, {Stephen D.} and Patrick Loehrer and Lawrence Einhorn and Tricot, {Guido J K}",
year = "1992",
month = "7",
day = "15",
language = "English",
volume = "117",
pages = "124--128",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "2",

}

TY - JOUR

T1 - Long-term outcome of patients with relapsed and refractory germ cell tumors treated with high-dose chemotherapy and autologous bone marrow rescue

AU - Broun, E. Randolph

AU - Nichols, Craig R.

AU - Kneebone, Patricia

AU - Williams, Stephen D.

AU - Loehrer, Patrick

AU - Einhorn, Lawrence

AU - Tricot, Guido J K

PY - 1992/7/15

Y1 - 1992/7/15

N2 - Objective: To review the long-term outcome of patients with recurrent and refractory germ cell tumors treated with high-dose chemotherapy and autologous bone marrow rescue. ■ Design: Cohort study. ■ Setting: A university hospital. ■ Patients: Forty consecutive patients with recurrent or refractory germ cell tumors treated at Indiana University between September 1986 and June 1989. ■ Interventions: Patients were treated with high-dose carboplatin (900 to 2000 mg/m2 body surface area) and etoposide (1200 mg/m2). Three patients also received ifosfamide (10g/m2). All patients had autologous bone marrow rescue. Of the 40 study patients, 26 received two full courses of therapy. ■ Measurements: Patient charts were reviewed to determine the rate and duration of complete and partial remission and the number of long-term, disease-free survivors. The influence of cisplatin-refractory disease and the site of the primary tumor on the incidence of remission and survival were also investigated. ■ Results: Of the 40 study patients, 26 (65%) responded to treatment; 12 (30%) achieved a complete response, and 14 (35%) achieved a partial response. Of the 12 complete responders, 5 relapsed, and 1 died of treatment-related acute leukemia 27.5 months after treatment without evidence of germ cell cancer. Six (15%) of the original 40 patients, of whom 3 were refractory to cisplatin, remained in complete remission after at least 24 months of follow-up. Eight of 40 patients had primary mediastinal germ cell tumors with no complete remissions and a median survival of 2 months (range, 0.5 to 9.0 months). ■ Conclusions: Treatment with high-dose carboplatin and etoposide in conjunction with autologous bone marrow rescue in patients with relapsed or refractory germ cell tumors is a potentially curative therapeutic option, even for heavily pretreated or cisplatin-refractory patients. Some degree of disease resistance to cisplatin can be overcome with dose escalation of platinum compounds. Patients with multiple recurrences of relapsed or refractory primary mediastinal germ cell tumors were not helped by this approach.

AB - Objective: To review the long-term outcome of patients with recurrent and refractory germ cell tumors treated with high-dose chemotherapy and autologous bone marrow rescue. ■ Design: Cohort study. ■ Setting: A university hospital. ■ Patients: Forty consecutive patients with recurrent or refractory germ cell tumors treated at Indiana University between September 1986 and June 1989. ■ Interventions: Patients were treated with high-dose carboplatin (900 to 2000 mg/m2 body surface area) and etoposide (1200 mg/m2). Three patients also received ifosfamide (10g/m2). All patients had autologous bone marrow rescue. Of the 40 study patients, 26 received two full courses of therapy. ■ Measurements: Patient charts were reviewed to determine the rate and duration of complete and partial remission and the number of long-term, disease-free survivors. The influence of cisplatin-refractory disease and the site of the primary tumor on the incidence of remission and survival were also investigated. ■ Results: Of the 40 study patients, 26 (65%) responded to treatment; 12 (30%) achieved a complete response, and 14 (35%) achieved a partial response. Of the 12 complete responders, 5 relapsed, and 1 died of treatment-related acute leukemia 27.5 months after treatment without evidence of germ cell cancer. Six (15%) of the original 40 patients, of whom 3 were refractory to cisplatin, remained in complete remission after at least 24 months of follow-up. Eight of 40 patients had primary mediastinal germ cell tumors with no complete remissions and a median survival of 2 months (range, 0.5 to 9.0 months). ■ Conclusions: Treatment with high-dose carboplatin and etoposide in conjunction with autologous bone marrow rescue in patients with relapsed or refractory germ cell tumors is a potentially curative therapeutic option, even for heavily pretreated or cisplatin-refractory patients. Some degree of disease resistance to cisplatin can be overcome with dose escalation of platinum compounds. Patients with multiple recurrences of relapsed or refractory primary mediastinal germ cell tumors were not helped by this approach.

UR - http://www.scopus.com/inward/record.url?scp=0026729352&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026729352&partnerID=8YFLogxK

M3 - Article

C2 - 1318648

AN - SCOPUS:0026729352

VL - 117

SP - 124

EP - 128

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 2

ER -